Vertex rushes to assure Wall Street that Jeff Leiden is keeping a hand on the reins as one analyst questions succession plans
Whatever his critics may have had to say about him, Jeff Leiden was deeply respected and more than a little revered on Wall Street as a CEO of a large public company who delivered on everything that mattered. The only evidence that really matters: Vertex’s stock quadrupled under his guidance. It’s a tough act to follow — and a top analyst who’s covered the company for years is raising questions about whether his newly designated successor is up to the job.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.